This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options
by Zacks Equity Research
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
Drug Pricing in Focus Again as Trump Tweet Slams Pfizer
by Kinjel Shah
In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
by Zacks Equity Research
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.
Company News For Jun 19, 2018
by Zacks Equity Research
Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA
Valeant (VRX) Up 19.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa
by Zacks Equity Research
Aerie (AERI) reported a narrower-than-expected loss in the first quarter. The launch of the lead drug Rhopressa is underway.
Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Implied Volatility Surging for Valeant (VRX) Stock Options
by Zacks Equity Research
Valeant (VRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Why Is Valeant (VRX) Up 4.3% Since Its Last Earnings Report?
by Zacks Equity Research
Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?
by Zacks Equity Research
Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.
Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Valeant (VRX) stock based on the movements in the options market lately.
Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses
by Zacks Equity Research
Aerie (AERI) incurs a wider-than-expected loss in the fourth quarter due to higher operating expenses.
Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?
by Zacks Equity Research
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
Valeant (VRX) to Settle Allergan Litigation for $290 Million
by Zacks Equity Research
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.
Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio
by Zacks Equity Research
Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.
Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder
by Zacks Equity Research
Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?
by Zacks Equity Research
Surging implied volatility makes Valeant Pharmaceuticals (VRX) stock lucrative to the option traders.
Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa
by Zacks Equity Research
Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, ahead of schedule.
Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?
by Ryan McQueeney
Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?
Valeant (VRX) in Focus: Stock Moves 11.7% Higher
by Zacks Equity Research
Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Implied Volatility Surging for Valeant (VRX) Stock Options
by Zacks Equity Research
Valeant (VRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Valeant Closes Senior Note Offering, Reprices Term Loan
by Zacks Equity Research
Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.
Can Valeant (VRX) Turn Around on Rebuilding Initiatives?
by Zacks Equity Research
Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.
Valeant (VRX) Announces Pricing of Senior Secured Notes
by Zacks Equity Research
Valeant (VRX) prices its senior secured notes. The proceeds of the notes will be used to pay down its existing debt.
Bear of the Day: Herbalife (HLF)
by Kevin Cook
As Ackman covers his short stock position and limps into puts, Wall Street banks are getting quieter too